Loxijas 30mg Tablet contains Duloxetine 30mg, a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. Duloxetine acts by increasing the levels of serotonin and norepinephrine in the central nervous system, thereby modulating mood and pain perception. Loxijas is administered orally, with the dosage tailored according to the patient’s clinical condition and response to therapy. Common adverse effects may include nausea, dry mouth, dizziness, somnolence, and constipation, which are generally mild to moderate and tend to diminish with continued use. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with uncontrolled narrow-angle glaucoma or those receiving monoamine oxidase inhibitors. Regular monitoring is recommended to assess therapeutic efficacy and detect any potential side effects. Abrupt discontinuation should be avoided to prevent withdrawal symptoms. Loxijas 30mg Tablet should be used under medical supervision, with careful consideration of the patient’s medical history and concomitant medications to minimize the risk of drug interactions and ensure optimal therapeutic outcomes.